Dollar Tree is down 9% on the week and 13% over the past month — a sharper slide than almost anything in its peer group — while shorts are quietly covering and the Street's post-earnings optimism looks increasingly stale.
The peer contrast sharpens the pain. Closest comparable Dollar General shed just 2.5% on the week, and Target dropped 5%. BJ's Wholesale actually gained nearly 6%. Dollar Tree's 9% decline isn't a sector story — it's a Dollar Tree story, and the question is what's driving it when positioning data suggests shorts aren't the culprit.
The lending market tells a notably unbothered story. Short interest has fallen sharply — down 13% on the week and more than 33% over the past month, bringing it to just 3.3% of the free float. Borrow availability is extraordinarily loose at roughly 6,000% of short interest, meaning there are nearly sixty shares available to lend for every one currently borrowed. That's the loosest it has been all year — the 52-week minimum availability was 382%. Cost to borrow has ticked up 31% on the week to 0.55%, but that remains firmly in "low" territory. The ORTEX short score has also drifted lower, from 37.3 a week ago to 34.7 today. None of this points to short sellers engineering the selloff — if anything, they've been reducing exposure as the stock fell.
Options positioning is equally unconcerned. The put/call ratio has actually moved in the bullish direction this week, hitting 0.70 — about one standard deviation below its 20-day average of 0.74. Options traders aren't rushing to buy protection into the drop. The PCR sits near its 52-week low of 0.61, far from the 1.39 high seen earlier in the year. The combination of short covering and a soft PCR makes this a price-only selloff, not a positioning-driven one.
The Street view is mixed but broadly constructive — which makes the price action harder to reconcile. Following the August earnings print, a wave of analysts lifted targets: Barclays raised to $160, UBS to $150, Wells Fargo to $155, and Morgan Stanley to $145. The consensus price target now rests around $136, implying roughly 21% upside from the current $112.79 close. The most recent move was Barclays on September 4, the only change in the past two weeks. Bulls point to the multi-price strategy, private-label momentum, and easing tariff pressures. Bears flag tariff-refund headwinds dragging on comp sales and EPS in the near term, and BMO Capital maintains an Underperform with a $98 target. The PE multiple has compressed to around 15x, down roughly 2.3 turns over the past month, suggesting the market is discounting the earnings recovery the bulls are pricing in.
The most structurally notable development is on the activist register. Paul Hilal, who filed a Schedule 13D in July 2025 disclosing a 6.5% stake, amended that filing in June 2026 showing his position had fallen to just 0.1% — essentially a full exit. The original 13D signalled activist intent; its near-complete dissolution removes that pressure from both directions. Hilal's departure may partly explain the loss of a potential catalyst that had been embedded in the share price. As always, 13D/G disclosures reflect positions as last filed — stakes near or below the 5% threshold may not generate further filings.
FMR (Fidelity) remains the dominant holder at nearly 13% of shares, having added over 4.6 million shares as recently as August 31. That's the clearest sign of institutional conviction on the register. With next earnings not until late November, the stock enters a long quiet period — and how quickly the gap between the $112 price and the $136 consensus target either closes or widens will depend on whether the August earnings thesis on tariff relief and comp recovery holds through the next data points.
See the live data behind this article on ORTEX.
Open DLTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
